ASTRO: Nucletron introduces new VMAT solution

TriMed Staff | | Health Imaging | Oncology Imaging
Nucletron has launched its new treatment radiation oncology planning solution for rotational therapy, the Oncentra volumetric modulated arc therapy (VMAT), at the American Society for Radiation Oncology’s (ASTRO) annual conference this week in Chicago.

The open planning solution, within the Oncentra external beam treatment planning system, supports image-guided photon, electron and proton treatment delivery, according to the Utrecht, Netherlands-based company.

“The recent addition enabling VMAT to the Oncentra treatment planning system reinforces the multimodality planning capability of Oncentra that includes brachytherapy and external beam treatments as well,” said Jos Lamers, CEO of Nucletron.

    TriMed Staff

    Related Content

    MRI guidance significantly reduces radiotherapy side effects compared to CT
    Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
    AI tumor volume estimations could improve prostate cancer treatment strategies
    MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
    Breast cancer only visible via MRI is often less aggressive
    Breast cancer rates are on the rise, new report reveals

    Around the web

    Cardiovascular Business
    Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

    Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

    Cardiovascular Business
    Global shortage of nuclear imaging isotopes may be over

    The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

    Cardiovascular Business
    ‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

    CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.